Recent trends in disease severity and quality of life instruments for patients with atopic dermatitis: A systematic review

Mary K. Hill, Azin Kheirandish Pishkenari, Taylor L. Braunberger, April W. Armstrong, Cory A. Dunnick

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background A significant number of instruments exist that are aimed at quantifying atopic dermatitis (AD) outcomes. Objective We sought to assess recent trends in the use of disease severity and quality of life (QOL) outcome instruments in randomized controlled trials (RCTs) conducted on patients with AD between July 2010 and July 2015. Methods A total of 540 nonduplicate records were identified through searches of Scopus and Ovid MEDLINE. Included studies were RCTs conducted on humans with AD that were published in English between July 2010 and July 2015 and that reported the results of disease severity or QOL outcome measures. Results All of the 135 included studies assessed disease severity. Only 45 studies assessed QOL. Sixty-two disease severity measures and 28 QOL scales were identified. Limitations This study was limited by its timeframe of 5 years and by the exclusion of non-RCTs and gray literature. Conclusion Disease severity and QOL outcome measures are instrumental in evaluating AD treatment efficacy. The number of such tools used in RCTs on patients with AD continues to rise. Standardization of outcomes instruments is essential for comparability among studies and improved quality of evidence.

Original languageEnglish (US)
Pages (from-to)906-917
Number of pages12
JournalJournal of the American Academy of Dermatology
Volume75
Issue number5
DOIs
StatePublished - Nov 1 2016
Externally publishedYes

Fingerprint

Atopic Dermatitis
Quality of Life
Randomized Controlled Trials
Outcome Assessment (Health Care)
MEDLINE

ASJC Scopus subject areas

  • Dermatology

Cite this

Recent trends in disease severity and quality of life instruments for patients with atopic dermatitis : A systematic review. / Hill, Mary K.; Kheirandish Pishkenari, Azin; Braunberger, Taylor L.; Armstrong, April W.; Dunnick, Cory A.

In: Journal of the American Academy of Dermatology, Vol. 75, No. 5, 01.11.2016, p. 906-917.

Research output: Contribution to journalArticle

Hill, Mary K. ; Kheirandish Pishkenari, Azin ; Braunberger, Taylor L. ; Armstrong, April W. ; Dunnick, Cory A. / Recent trends in disease severity and quality of life instruments for patients with atopic dermatitis : A systematic review. In: Journal of the American Academy of Dermatology. 2016 ; Vol. 75, No. 5. pp. 906-917.
@article{42dd5159273d4d1fae7e0d4f7dde545e,
title = "Recent trends in disease severity and quality of life instruments for patients with atopic dermatitis: A systematic review",
abstract = "Background A significant number of instruments exist that are aimed at quantifying atopic dermatitis (AD) outcomes. Objective We sought to assess recent trends in the use of disease severity and quality of life (QOL) outcome instruments in randomized controlled trials (RCTs) conducted on patients with AD between July 2010 and July 2015. Methods A total of 540 nonduplicate records were identified through searches of Scopus and Ovid MEDLINE. Included studies were RCTs conducted on humans with AD that were published in English between July 2010 and July 2015 and that reported the results of disease severity or QOL outcome measures. Results All of the 135 included studies assessed disease severity. Only 45 studies assessed QOL. Sixty-two disease severity measures and 28 QOL scales were identified. Limitations This study was limited by its timeframe of 5 years and by the exclusion of non-RCTs and gray literature. Conclusion Disease severity and QOL outcome measures are instrumental in evaluating AD treatment efficacy. The number of such tools used in RCTs on patients with AD continues to rise. Standardization of outcomes instruments is essential for comparability among studies and improved quality of evidence.",
author = "Hill, {Mary K.} and {Kheirandish Pishkenari}, Azin and Braunberger, {Taylor L.} and Armstrong, {April W.} and Dunnick, {Cory A.}",
year = "2016",
month = "11",
day = "1",
doi = "10.1016/j.jaad.2016.07.002",
language = "English (US)",
volume = "75",
pages = "906--917",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Recent trends in disease severity and quality of life instruments for patients with atopic dermatitis

T2 - A systematic review

AU - Hill, Mary K.

AU - Kheirandish Pishkenari, Azin

AU - Braunberger, Taylor L.

AU - Armstrong, April W.

AU - Dunnick, Cory A.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Background A significant number of instruments exist that are aimed at quantifying atopic dermatitis (AD) outcomes. Objective We sought to assess recent trends in the use of disease severity and quality of life (QOL) outcome instruments in randomized controlled trials (RCTs) conducted on patients with AD between July 2010 and July 2015. Methods A total of 540 nonduplicate records were identified through searches of Scopus and Ovid MEDLINE. Included studies were RCTs conducted on humans with AD that were published in English between July 2010 and July 2015 and that reported the results of disease severity or QOL outcome measures. Results All of the 135 included studies assessed disease severity. Only 45 studies assessed QOL. Sixty-two disease severity measures and 28 QOL scales were identified. Limitations This study was limited by its timeframe of 5 years and by the exclusion of non-RCTs and gray literature. Conclusion Disease severity and QOL outcome measures are instrumental in evaluating AD treatment efficacy. The number of such tools used in RCTs on patients with AD continues to rise. Standardization of outcomes instruments is essential for comparability among studies and improved quality of evidence.

AB - Background A significant number of instruments exist that are aimed at quantifying atopic dermatitis (AD) outcomes. Objective We sought to assess recent trends in the use of disease severity and quality of life (QOL) outcome instruments in randomized controlled trials (RCTs) conducted on patients with AD between July 2010 and July 2015. Methods A total of 540 nonduplicate records were identified through searches of Scopus and Ovid MEDLINE. Included studies were RCTs conducted on humans with AD that were published in English between July 2010 and July 2015 and that reported the results of disease severity or QOL outcome measures. Results All of the 135 included studies assessed disease severity. Only 45 studies assessed QOL. Sixty-two disease severity measures and 28 QOL scales were identified. Limitations This study was limited by its timeframe of 5 years and by the exclusion of non-RCTs and gray literature. Conclusion Disease severity and QOL outcome measures are instrumental in evaluating AD treatment efficacy. The number of such tools used in RCTs on patients with AD continues to rise. Standardization of outcomes instruments is essential for comparability among studies and improved quality of evidence.

UR - http://www.scopus.com/inward/record.url?scp=84994875656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994875656&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2016.07.002

DO - 10.1016/j.jaad.2016.07.002

M3 - Article

AN - SCOPUS:84994875656

VL - 75

SP - 906

EP - 917

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 5

ER -